Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma

Ibrutinib (Imbruvica®), a small-drug inhibitor of Bruton tyrosine kinase (BTK), is currently undergoing clinical testing in patients with multiple myeloma (MM), yet important questions on the role of BTK in myeloma biology and treatment are outstanding. Using flow-sorted side population (SP) cells f...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Yang, Ye, Shi, Jumei, Gu, Zhimin, Salama, Mohamed E, Das, Satyabrata, Wendlandt, Erik, Xu, Hongwei, Huang, Junwei, Tao, Yi, Hao, Mu, Franqui, Reinaldo, Levasseur, Dana, Janz, Siegfried, Tricot, Guido, Zhan, Fenghuang
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384656/
https://ncbi.nlm.nih.gov/pubmed/25589346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2362
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares